BMS And Prothena’s Expanded Deal Shows Growing Confidence In Targeting Tau

But First Clinical Benefits Yet To Be Seen

After serial failures with tau antibodies for Alzheimer’s, BMS’ expanded deal with Prothena signals its growing confidence in PRX005, a new molecule targeting a different region on the toxic protein.

BMS

Bristol Myers Squibb has opted to buy the global rights to Prothena’s anti-tau Alzheimer’s candidate PRX005, paying $55m to expand an existing US-only deal.

There have been scores of failed tau-targeting candidates over the last two decades, but enhanced understanding of how to target...

More from Deals

More from Business